

Spirify Pharma Announces Closing of Successful Seed Funding Round

The Company Raises Seed Funding to Expand Its Operations Manufacture and Test It's Lead Compounds

PRESS RELEASE UPDATED: JULY 27, 2021

NAPLES, FLORIDA, JULY 27, 2021 (Newswire.com) – Spirify Pharma, Inc., a pre-clinical stage pharmaceutical company dedicated to developing novel therapies for CNS diseases including pain, depression, and certain neurodegenerative diseases, announced today that it has successfully closed its seed funding round.

"We are very pleased to have accomplished this important milestone for the Company and to see investor confidence in our family of molecules and development program" stated Sigal Kremer-Tal, M.D., Chief Executive Officer of Spirify. "We are well-positioned to move forward with our plans to further capitalize the Company and achieve significant development milestones in the year ahead."

"This successful seed round is another validation of the potential for Spirify's novel drug compounds," said Irving Wainer, Ph.D., Spirify's Co-Founder and Chief Science Officer. "We have already started to deploy these funds to advance our pre-clinical program, including the manufacturing and testing of our lead compounds."

About Spirify Pharma Inc.

Spirify Pharma, Inc. is a pharmaceutical company dedicated to transforming the way pain and depression are treated by developing novel therapeutics based on HNK derivative compounds. Spirify is based in Naples, Florida. More information can be found by visiting the Spirify website at www.spirifypharma.com.

Contact:

Sigal Kremer-Tal, MD - CEO & Co-founder
stal@spirifypharma.com